Categories: CancerNews

Invitation to presentation of RaySearch’s interim report for the first quarter of 2025

FacebookFacebookTwitterTwitterEmailEmailLinkedInLinkedInWhatsAppWhatsAppMessengerMessengerFlipboardFlipboardGmailGmailTelegramTelegramShareShare

STOCKHOLM, April 25, 2025 /PRNewswire/ — Analysts, investors, and the media are invited to a presentation of RaySearch’s interim report for the first quarter of 2025, on May 9, 2025, at 10.00 am CEST. The report will be published on May 9, 2025, at 07.45 am and will be available together with presentation slides on raysearchlabs.com. Johan Löf, founder and CEO, and Nina Grönberg, CFO, will present the company’s development in a webcast. After the presentation (held in English) there is the opportunity to ask questions.

Link to webcast: RaySearch Q1, 2025

For more information, please contact: 

Johan Löf, founder and CEO, RaySearch Laboratories AB (publ) 
Telephone: +46 (0) 8 510 530 00
johan.lof@raysearchlabs.com  

Nina Grönberg, CFO, RaySearch Laboratories AB (publ)
Tel: +46 (0) 8 510 530 00
nina.gronberg@raysearchlabs.com

About RaySearch

RaySearch Laboratories AB (publ) is a medical technology company that develops innovative software solutions for improved cancer treatment. RaySearch markets the RayStation®* treatment planning system (TPS) and the oncology information system (OIS) RayCare®*. The most recent additions to the RaySearch product line are RayIntelligence® and RayCommand®*. RayIntelligence is an oncology analytics system (OAS) which enables cancer clinics to collect, structure and analyze data. RayCommand, a treatment control system (TCS), is designed to link the treatment machine and the treatment planning and oncology information systems. 

RaySearch’s software has been sold to over 1,100 clinics in 47 countries. The company was founded in 2000 as a spin-off from the Karolinska Institute in Stockholm and the share has been listed on Nasdaq Stockholm since 2003. More information is available at raysearchlabs.com.

* Subject to regulatory clearance in some markets. 

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/raysearch-laboratories/r/invitation-to-presentation-of-raysearch-s-interim-report-for-the-first-quarter-of-2025,c4138575

The following files are available for download:

https://mb.cision.com/Main/1102/4138575/3409313.pdf

RaySearch Press Release Q1 2025 invitation presentation

View original content:https://www.prnewswire.com/news-releases/invitation-to-presentation-of-raysearchs-interim-report-for-the-first-quarter-of-2025-302438284.html

SOURCE RaySearch Laboratories

Staff

Recent Posts

Best Supplements For Muscle Growth: Top Legal Bodybuilding Supplements & Anabolic Steroids For Bulking, Cutting & Strength

Backed by Wolfson Brands (UK) Limited, Discover the best supplements for muscle growth, including top…

23 minutes ago

Mitolyn Reviews 2025: Exploring Faux Reviews, Consumer Complaints, & How to Buy Real Mitolyn Purple Peel Exploit!

Mitolyn Mitolyn Seattle, May 03, 2025 (GLOBE NEWSWIRE) -- As more individuals become health-conscious, and…

23 minutes ago

Buy Ibutamoren MK 677 SARMS for Sale Online: MK-677 Before After Results – Where to Order Legal Ibutamoren SARM OTC, Buyers Guide from CrazyBulk

CrazyBulk CrazyBulk New York City, May 03, 2025 (GLOBE NEWSWIRE) -- If you’re serious about…

23 minutes ago

Bioma Review 2025: Revolutionizing Gut Health or Just Another Fad? Honest Analysis Inside By Bioma Probiotic!

Gut transformation through Bioma a perfectly blended combination of probiotics prebiotics and postbiotics Bioma Bioma…

23 minutes ago

IBA launches QUASAR® GRID3D Advantage Image Distortion Analysis System

New standard in the Quality Assurance of image distortion for MR guided radiation therapy and MR…

23 minutes ago

Endogenex Highlights 48-Week REGENT-1 Clinical Study Results at Digestive Disease Week 2025

Novel Endoscopic Procedure Demonstrates Substantial and Durable Reduction in Insulin Resistance and Improvement in Beta…

1 day ago